Navigation Links
Is governmental investment in industrial R&D paying off?
Date:7/1/2011

June 30, 2011 Jerusalem, Israel The Israeli Chairmanship of EUREKA, the largest pan-European network for market-oriented, industrial R&D and innovation, has released new data from a report conducted by Kalman Gayer and the economic and strategic consulting firm Applied Economics Ltd., to mark the completion of Israel's Chairmanship year and EUREKA's 25th anniversary. The study presents the proven impact of EUREKA on companies participating in EUREKA programs.

Israel Shamay, Director of the Israeli Chairmanship of EUREKA, explained that the surveys previously conducted by various European R&D programs, including EUREKA, were based largely on interviews with managers and/or technical summary reports of the project, which naturally focused on the tools of R&D and less on financial results. "Since the Israeli Chairmanship does not consider industrial R&D an end in it of itself, but rather as a means to advance industry and economic growth through innovation and international cooperation, we decided to measure the financial effect of participation in the program for the firm."

Geyer's study measured the impact of participation in EUREKA projects for companies in Europe. The study is based on a sample of 350 companies which participated in EUREKA projects between 1996 and 2005. The study compares pairs of companies nearly identical in their parameters: size, country, field of technology, sales revenue, number of employees, etc. - with the key difference between them being that one company having participated in at least one EUREKA project, and the other company having not participated. The difference in outcomes (after the EUREKA project is completed) between the participating company and the non-participating company is attributed to the effect of participation in EUREKA. The research examined individual cooperation projects that were performed mostly by two partners from 2 countries, and that focused on industrial R&D - products close to market. This is the main support vessel, characteristic of most of the activities taking place in the program.

Dr. Shaul Freireich, Deputy Chief Scientist of Technology, oversaw the execution of the survey on behalf of the Israeli Chairmanship.

The study focused on changes in sales volume and number of employees at the company, showing significant results on the impact of EUREKA participation in both of these parameters. On average, companies participating in EUREKA recorded sales that rose by 28% annually during the three years from the completion of the project, compared to similar companies which did not participate during this period as part of EUREKA project. Additionally, there was an annual increase in employment in these companies by 20% or more, compared to similar companies not involved in EUREKA at the time. Overall, approximately two-thirds of companies that participated in EUREKA projects outperformed similar but non-participating companies, in terms of both sales and employment.

The positive impact of EUREKA was shown to be significant upon both large companies and SMEs, with the statistics for sales and employment growth being greater fir medium and large companies.

According to Luuk Borg, Director of the EUREKA Secretariat based in Brussels, the survey shows that the total annual increase in sales among companies participating in EUREKA projects is approximately 2.8 billion euros, in addition to 25,000 jobs created each year - while the annual governmental aggregate investment (from the 40 EUREKA member countries) in these projects stands at about 140 million euros only.

The Israeli angle in the study: The sample included 30 Israeli companies. The comparison was made between firms that received regular grants from the Office of the Chief Scientist, and the 'twin' companies that were supported by the OCS as part of participation in the EUREKA project, in order to measure the added economic value of EUREKA participation beyond that of normal government support for R&D. The results of the survey initiated by the Israeli Chairmanship of EUREKA are supported by other studies conducted during the Israeli Chairmanship year by other countries including Spain, France and Denmark.


'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@eurekanetwork.org
322-777-0979
EUREKA
Source:Eurekalert

Related biology news :

1. Georgia residents: Investment in global health research is vital to states economy
2. Life Sciences Venture Capital Investment Level Rebounds in Q1 2011 but Deal Volume Declines, According to the MoneyTree Report
3. Measuring science investments
4. President Obama calls for increased investment in science, including biomedical research
5. Stroz Friedberg Amplifying Growth with $115MM New Mountain Capital Investment
6. Stroz Friedberg Amplifying Growth with $115MM New Mountain Capital Investment
7. Wellcome-Wolfson partnership makes £30 million investment in UK scientific infrastructure
8. Endeavour to Present at Rodman & Renshaw Global Investment Conference
9. Caltech receives more than $33 million from American Recovery and Reinvestment Act
10. NASDCTEc and ACTE Ask the White House to Increase Investment in, Not Flat Fund, CTE
11. Iowa State faculty attract $4.8 million in American Recovery and Reinvestment Act grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology: